Connect with us


The Endocannabinoid System and Pain Sensitivity



People in this world today don’t necessarily agree on much. But one thing we can all agree on is that pain isn’t a lot of fun. Hence, billions of dollars gets poured into research every year on how to control and manage pain.

Due to the vital and integral role played by the endocannabinoid system in so many different important systemic processes in human physiology, new research has begun to show that the endocannabinoid system is intimately tied in to pain sensitivity.

To understand why, we need to understand a little bit more about pain.

Understanding Pain

While we don’t like pain, it turns out that pain is an important tool in the toolbox that evolution has equipped us with to maximize our survival potential. If you didn’t have pain, you wouldn’t have a problem standing on a burning fire. Yet the fire would still burn your tissue and ultimately kill you. It is the pain that causes you to jump aside.

Pain is discomfort meant to remove us from danger.

Pain is also a valuable teacher, educating us in our young lives about the sorts of things that are good for us to do. Repeated exposure to pain associated with a particular behavior is a good way to teach us to no longer exhibit that behavior. And evolution has equipped us with pain sensors generally designed to teach us that lesson whenever a behavior is potentially dangerous.

There are two types of pain to consider: acute pain, and chronic pain.

Acute pain is something that doesn’t last very long and is generally associated with some sort of immediate physical trauma.

Chronic pain, on the other hand, is a lingering pain that can sustain itself for long periods. This form of pain is generally considered a pathology in and of itself.

In addition, you’ll find that the relationship between the severity of pain and the cause of that pain is usually a relationship defined by the ultimate existential danger underlying that source of pain. In other words, something that isn’t very dangerous or harmful to the body usually isn’t as painful as something that could possibly kill us.

The Physiology of Pain

As noted above, pain can be understood best as information. As such, it is carried through the central nervous system from areas of the body to the brain.

Pain is ultimately a cognitive experience. The network of nerves that make up the peripheral nervous system represent an important pathway of sensation that allows us to understand both pressure and pain.

As the information of pain gets carried up the peripheral nervous system and into the brain, our brain is able to process that information both in terms of the severity and danger level as well as the area of the body that it is coming from. That information can then be used to trigger an instinctive or cognitive response.

The overall level of sensitivity that an individual has to pain is usually something that is genetic in nature. In other words, some people are far more sensitive to pain than others.

The Endocannabinoid System and Pain Sensitivity

Recent research has shown that the endocannabinoid system is intimately integrated into the pain tolerance system of the body. In fact, in one study, rats were subject to a blocking of their CB1 receptors through the use of an antagonist.

That experiment showed that those rats with the blocked receptor experienced an increase in their overall sensitivity to pain (known as hyperalgesia). That has strongly suggested that the endocannabinoid system is involved in the suppression of oversensitivity to pain.

In addition, much research has shown the powerful role that THC can play in managing the experience of pain through the stimulation of beta endorphin production. The most significant aspect of this research is that it can prevent addiction to opiates by blocking tolerance development and withdrawal symptoms.

By implication, all of this research suggests that a deficiency of the endocannabinoid system can be a prime source of hyperalgesia – or an overabundance of pain sensitivity. This also suggests that those suffering from too much pain sensitivity may benefit by the introduction of CBD, thus rebalancing the overall functionality of the endocannabinoid system.

This has opened up an exciting area of research for scientists involved in the field of pain and pain sensitivity, and simultaneously cast another spotlight on the promising potential of treatments involving the endocannabinoid system.


WeedMD Inc (OTCMKTS:WDDMF) Rolls Out Its Color Cannabis Brand For Adults



WeedMD Inc (OTCMKTS:WDDMF) has announced the launch of its latest brand called Color Cannabis as a premium brand that targets adult users that want high-grade cannabis products.

The new Color Cannabis premium brand features numerous strains of cannabis that are presented in multiple formats. However, they are also developed such that they have a high level of quality as per the expectations of the target consumers. WeedMD’s new brand will only be available to a few distributors and retailers in Canada.

WeedMD plans to have the Color Cannabis-branded products in select stores as well as online availability by Mid-June. The company created the brand with a strategic aim at the diverse preference and tastes of the modern-day cannabis consumer.

“We worked with globally-renowned agency Sid Lee to launch Color – our first adult-use brand,” stated Brett Moon, the Senior Vice President of sales and marketing at WeedMD.

The Color Cannabis brand to mainly focus on a premium user experience

Mr. Moon also noted that Color Cannabis is designed to inspire customers to embrace life and their cannabis experience in personal and unique ways. Aside from being available in the form of dried premium flower, the new WeedMD brand also hosts new product formats over the next few months. Some of those products include gel capsules, oils and pre-rolls and they will be made available with the creation of more consumption formats.

WeedMD CEO Keith Merker stated that Color Cannabis’ goal is to grasp the progressive character, individuality, and imagination of cannabis users. The CEO noted that the goal of the brand is not to tell clients what they will feel but rather to experience the products for themselves. Merker also noted that the Color Cannabis launch represents a key milestone for the company.

WeedMD expects to juggle between the new adult cannabis brand and its medical cannabis pursuits. The company expects to produce about 150,000 kilograms through its 5.2 million square feet production capacity by 2020. The firm also expects to have enough room to handle production for medical cannabis, as well as recreational adult use. It plans to achieve this through its indoor and outdoor growth facilities.

Continue Reading


HempAmericana Inc. (OTCMKTS:HMPQ) CEO Issues Explains The Company’s Expansion



HempAmericana Inc. (OTCMKTS:HMPQ) CEO has issued a letter to shareholders addressing the expansion of the company following string orders.

HempAmericana has begun bottling of full-spectrum CBD distillate

In the letter to shareholders, the CEO indicated that the company has begun establishing growth momentum in its CBD oil production as well as the distribution business. The CEO stated that the company has started bottling of 500 mg as well as 1000 mg full spectrum CBD distillate in its ultramodern CBD production and extraction facility in Augusta Maine.

He added that the company’s initial production is expected to be around 2,000 bottles per day which will be increased gradually to around 8,000 bottles a day to meet demand. Currently, the company has more than 50,000 full spectrum distillate bottles that are ready to be shipped with tens of thousands expected to follow.

HempAmericana is equally bottling a 250 mg potency that is suitable for the CBD-for-pets market. On the high end, the CEO indicated that the company is bottling 2500 mg and 5000 mg but he asserted that they have the potential of replicating any formula.

The CEO further went on to explain that production will be distributed under the company’s proprietary brand “Weed Got Oil.” He added that the company is also pursuing an opportunity in the white label market for the quality full-spectrum distillate CBD Oil. Currently, there are over 400 brands in the CBD market with the majority turning to high capacity producers such as HempAmericana to build product inventory.

Relationship with Eagle Hemp

The company recently announced a relationship with Florida based Eagle Hemp for an initial purchase order as well as the establishment of connections for more orders in the future. The company anticipates strong demand that includes compensation for more production of CBD oil as well as its bottling technology. The first order will bring the company significant revenue input at no associated costs to labeling, bottling, and shipping.

The company’s production facility and lab are currently operating well with two bottling machines in operation. The CEO said that once they distill the interest into purchase orders they will communicate to shareholders.

Continue Reading


Medmen Enterprises Inc. (OTCMKTS:MMNFF) Expands Its Footprint In California With Acquisition Of One Love



MedMen Enterprises Inc. (OTCMKTS:MMNFF) has announced the signing of a definitive agreement for the acquisition of 100% interest in MattnJeremy, Inc. One Love Beach Club.

Acquisition of One Love

The acquisition enhances the company’s California footprint by adding a premier location that is positioned strategically between its LAX and Santa Ana locations. The One Love Beach Club is currently on a run-rate of around $6 million in gross revenue and has an unaudited EBITDA margin of about 29%.

MedMen CEO Adam Bierman stated that they were delighted to have Long Beach on bard as part of the MedMen family as the company continues its growth in the world’s leading cannabis market.

One love was founded back in 2009 and it is located in Long Beach at 2767 E Broadway between Belmont Shore and Downtown some blocks from the beach. Long Beach is located 20 miles from Los Angeles and it is the third largest city in Southern California behind San Diego and Los Angeles with a population of almost half a million.

The city is a prime location that offers attractions, oceanfront hotels, events, recreation activities, shopping, nightly entertainment, restaurants as well as art and culture. According to the Long Beach Convention & Visitors Bureau in 2018 there were approximately 7.9 million visitors who visited the city to attend various events and attractions.

The One Love owner and operator Abrams Family indicated that it had been exciting to have served the Long Beach community for the last ten years adding that they were looking forward to MedMen to continue offering the community with premium cannabis.

Details of the transaction

According to the details of the transaction MedMen is expected to pay around $13 million of which $1 million will be in cash at closing of the deal and $2 million in deferred cash. The rest of the $10 million shall be fulfilled in Class B Subordinate Voting shares. Completion of the transactions depends on regulatory approval by state and local authorities as well as other routine closing conditions. The deal is expected to be closed within 45 days.

Continue Reading

Trending Stories